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S-nitrosoglutathione (GSNO) is an endogenous nitric oxide (NO) carrier that plays a critical role in redox
based NO signaling. Recent studies have reported that GSNO regulates the activities of STAT3 and NF-κB
via S-nitrosylation dependent mechanisms. Since STAT3 and NF-κB are key transcription factors involved
in tumor progression, chemoresistance, and metastasis of head and neck cancer, we investigated the
effect of GSNO in cell culture and mouse xenograft models of head and neck squamous cell carcinoma
(HNSCC). For the cell culture studies, three HNSCC cell lines were tested (SCC1, SCC14a and SCC22a). All
three cell lines had constitutively activated (phosphorylated) STAT3 (Tyr705). GSNO treatment of these
cell lines reversibly decreased the STAT3 phosphorylation in a concentration dependent manner. GSNO
treatment also decreased the basal and cytokine-stimulated activation of NF-κB in SCC14a cells and
reduced the basal low degree of nitrotyrosine by inhibition of inducible NO synthase (iNOS) expression.
The reduced STAT3/NF-κB activity by GSNO treatment was correlated with the decreased cell pro-
liferation and increased apoptosis of HNSCC cells. In HNSCC mouse xenograft model, the tumor growth
was reduced by systemic treatment with GSNO and was further reduced when the treatment was
combined with radiation and cisplatin. Accordingly, GSNO treatment also resulted in decreased levels of
phosphorylated STAT3. In summary, these studies demonstrate that GSNO treatment blocks the NF-κB
and STAT3 pathways which are responsible for cell survival, proliferation and that GSNO mediated
mechanisms complement cispaltin and radiation therapy, and thus could potentiate the therapeutic
effect in HNSCC.
& 2015 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Head and neck squamous cell carcinoma (HNSCC) is the sixth
most common cancer and one of the leading causes of cancer
deaths worldwide. Recent advances in the ﬁeld of HNSCC include
development of free ﬂaps for reconstruction after surgery orn open access article under the CC
de and Cancer, edited by Jordi
aboratory Medicine, Medical
tute Room #: 513, 173 Ashley
Medical University of South
3 Ashley Avenue, Charleston,
ghi@musc.edu (I. Singh).intensity modulated radiation therapy for targeted radiotherapy
[1,2]. However, the prognosis for these patients has not improved
signiﬁcantly. Therefore, better agents are needed to improve
therapeutic outcomes.
Aberrant or constitutive activation of STAT3 and NF-κB has
been detected in many human malignancies including HNSCC
[3,4,6]. STAT3 and NF-κB play key roles in the regulation of im-
mune/inﬂammatory responses, but growing evidence also sup-
ports a major role in oncogenesis [3,7]. Molecular targeting of
STAT3 by various methods, such as interfering in dimerization and
siRNA approaches, has been shown to inhibit tumor growth in
preclinical models of human cancer [8,9]. However, these are not
considered drug candidates because of uncertain feasibility of
these approaches in clinical practice. NF-κB has been implicated in
cancer progression by activation genes that stimulate cancer cell
proliferation and survival, angiogenesis, and metastases, and thusBY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cancer [4]. However, presently there is no effective treatment
strategy for managing the aberrant NF-κB activity in cancers.
While studying the inﬂammatory pathways in cell culture and
animal models of multiple sclerosis (experimental autoimmune
encephalomyelitis) and stroke (middle cerebral artery occlusion),
our laboratory reported that NF-κB activation under inﬂammatory
conditions is inhibited by S-nitrosylated glutathione (GSNO)
treatment [10,11]. Since NF-κB has been also reported to be
regulated by glutathionylation [12,13], these studies document the
roles of the cellular GSNO as well as redox potential in regulation
of NF-κB pathways. In addition, we have also recently reported
that STAT3 activation induced by IL-6 is inhibited by endogenously
generated nitric oxide (NO) from inducible NO synthase (iNOS) or
exogenously supplemented GSNO via S-nitrosylation of Cysteine
259 residue of STAT3 molecule, documenting that STAT3 S-ni-
trosylation is a physiological regulation [14]. We have also re-
ported that inhibition of STAT3 by GSNO is implicated in TH17
immunomodulation under EAE conditions [15] and anti-pro-
liferation of microglia and cancer cells [16,17]. GSNO is an en-
dogenous NO carrier which plays a crucial role in redox based
nitrosylation of protein thiols (S-nitrosylation) in health and dis-
ease [18] and is now recognized as an important cell signaling
mechanism [19]. Although NF-κB and STAT3 have been implicated
in tumorigenesis, metastasis, and chemoresistance [7,20], the
biological function of NO and GSNO in regulation of NF-κB and
STAT3 in cancer cells and their associated cell signaling pathways
leading to cancer progression are not understood well at present.
NO, synthesized by nitric oxide synthases (NOS), is shown to
have both pro- and anti-tumor activity [21–28]. These multi-
factorial effects may be manifested via a range of chemical mod-
iﬁcations caused by different properties of the source of NO levels
and its metabolites (NO2, NOþ , and NO) in nitration, nitrosation
or nitrosylation of target molecules as well as the redox environ-
ment of the tumor. However, the observed chemosensitization of
tumor by NO in doxorubicin resistance by nitroglycerine [27,28],
efﬁcacies of NO-nonsteroidal anti-inﬂammatory drugs [29] as well
as direct efﬁcacy of NO compounds in epithelial to messenchymal
transition in cancer cells [25], and inhibition of cell proliferation or
tumor growth by GSNO treatment in multiple myeloma cell lines
[16] and ovarian cancer xenografted mouse models [17] suggests
that NO compounds may be considered as potential therapeutic
agents for blocking the metastasis cascade and for treatment of
patients with refractory cancer. Understanding the different ac-
tions of NO and its metabolites in cancer at the molecular level can
provide insights in devising potential strategies for cancer
treatment.
Based on the fact that STAT3 and NF-κB are involved in tumor
growth, angiogenesis and invasion and that GSNO, an endogenous
nitrosylating agent, can inhibit activation of STAT3 [15] and NF-κB
[10,30], we investigated the efﬁcacy of GSNO in head and neck
cancer using HNSCC cells in vitro and in vivo xenograft models.
The studies described in this manuscript document that GSNO
treatment inhibits cell survival and proliferation in in vitro cul-
tures of HNSCC cells and also inhibits tumor growth in the xeno-
graft animal model. Moreover, GSNO mediated mechanisms
against tumor growth complement ionizing radiation and cisplatin
treatments to provide greater efﬁcacy. This study for the ﬁrst time,
documents that GSNO mediated inactivation of STAT3 signaling
pathway may prove to be of therapeutic potential in the treatment
of head and neck cancer.2. Materials and methods
2.1. Cell cultures
HNSCC cell lines UM-SCC-1 (retromolar trigone/ﬂoor of the
mouth; SCC1), UM-SCC-14A (SCC of anterior ﬂoor of the mouth;
SCC14a), and UM-SCC-22A (SCC of hypopharynx; SCC22a) were
obtained from Dr. Thomas Carey (Department of Otolaryngology/
Head and Neck Surgery, University of Michigan) [31]. These cells
lines were cultured in Dulbecco's Modiﬁed Eagle's Medium/Ham's
F-12 (50/50) (Mediatech Inc., Manassas, VA) with 10% fetal bovine
serum, 100 U/ml penicillin and 100 μg/mL streptomycin. The cells
were grown at 37 °C under 5% CO2/95% air.
2.2. Cell survival, cell proliferation, and cell cycle assay
The cells in 96-well culture plates in serum free medium were
treated with different doses of drugs/radiation. The fractions of the
surviving cells were measured by colorimetric assay using WST-8
tetrazolium salt (Cayman Chemical, Ann Arbor, MI). The amount of
formazan dye generated from WST-8 by the activity of dehy-
drogenases in cells was measured by SpectraMax 190 ELISA reader
(Molecular Devices, Sunnyvale, CA) at 450 nm. For cell prolifera-
tion assay, the cells were treated with 5-bromo-2′-deoxyuridine
(BrdU; 10 μM) for 4 h and BrdU incorporated into DNA was mea-
sured by colormetric BrdU assay kit (Cell Signaling Technology,
Danvers, MA) as per manufacturer's instruction. Cell cycle analysis
was performed by ﬂow cytometry following the staining of cells
with propidium iodide. Brieﬂy, the ethanol ﬁxed cells were treated
with RNase solution and then stained with propidium iodide
(50 μg/ml). The samples were analyzed by FACSCalibur™ ﬂow
cytometer with Cell QuestTM software (BD Biosciences, San Jose,
CA). Expression of cell survival and cell cycle regulators was
measured byWestern blot analysis using antibodies speciﬁc to Bcl-
xL, cIAP, and c-Myc (Cell Signaling Technology).
2.3. Assay for STAT3 activation
The activities of STAT3 were analyzed as Western analysis for
phosphorylated (Tyr705) STAT3 (pSTAT3) and total STAT3 with
speciﬁc antibodies (Cell Signaling Technologies, Danvers, MA). For
immunoﬂuorescent staining of pSTAT3/STAT3, SCC14a cells cul-
tured on chamber slides (LabTek, Nunc, Inc., Naperville, IL) were
ﬁxed in cold methanol and incubated with primary antibodies
against phospho- or pan-STAT3 and then secondary antibody (goat
anti-Rabbit IgG conjugated with DyLight 488 or 594) (Jackson
Immunoresearch Laboratories Inc. West Grove, PA). 4′,6-diamidi-
no-2-phenylindole (DAPI) was used for nuclei counter-stain. Im-
munoﬂuorescence images were captured by ﬂuorescent micro-
scope equipped with Olympus digital camera (Olympus BX-60,
Goleta, CA) and quantiﬁed by using Image-Pro 6.2 (Media Cyber-
netics, Silver Springs, MD). Identical illumination, microscope, and
camera settings were used to obtain images for quantiﬁcation.
2.4. Assay for NF-κB activation and HIF-1α accumulation
Nuclear and cytoplasmic extracts from SCC14a cells treated
with GSNO and/or cytokines were prepared using a previously
published method [32]. The cytoplasmic and nuclear levels of p65
NF-κB and HIF-1α were analyzed by Western analysis using spe-
ciﬁc antibodies (Cell Signaling Technologies). H3 histone and β-
actin were used for internal loading control for nuclear and cyto-
plasmic proteins. The nuclear protein extracts were also used for
the gel-shift assay for detection of NF-κB DNA binding activities.
The gel-shift assay for NF-κB DNA binding activity was performed
as described previously [32].
Fig. 1. Effect of GSNO treatment on STAT3 activation in HNSCC cells. (A) The HNSCC cells were treated with different concentrations of GSNO for 24 h and then levels of total
or phosphorylated (Tyr705) STAT3 (pSTAT3) (i) and their ratios (ii) were analyzed by Western analysis. (B) GSNO mediated reversible inhibition of STAT3 phosphorylation was
analyzed in SCC14a cell lines after single treatment with 250 mM GSNO. (C) SCC14a cells were treated with 250 μM GSNO for 3 h and then ﬁxed and labeled with STAT3 or
pSTAT3 antibodies (i) and the intensities of ﬂuorescence were quantiﬁed (ii). The results in bar and line graphs were given as mean of more than three independent
experiments. The vertical lines indicate the standard error of mean; *Po0.05; ***Po0.001; n.s. (not signiﬁcant) compared with vehicle treated control groups.
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and drug treatment
All animal studies were carried out in strict accordance with
the recommendations in the Guide for the Care and Use of La-
boratory Animals of the National Institutes of Health. The protocol
was approved by the Institutional Animal Care & Use Committee
(IACUC) of the Medical University of South Carolina (Permit
number: AR2830). The male athymic nude mouse (Hsd:Athymic
Nude-Foxn1nu) of age 5-6 weeks (Harlan Laboratories, Wilmington,
MA) were randomly allocated in eight groups (control, radiation,
cisplatin, radiationþcisplatin, GSNO, GSNOþradiation,
GSNOþcisplatin, GSNOþradiationþcisplatin; n¼6). For biolumi-
nescent imaging, SCC14a were stably transfected with ﬁreﬂy lu-
ciferase in pcDNA3 plasmid. Tumors were induced by injecting
0.1 ml luciferase expressing SCC14a cell (1106) suspension into
the ﬂank region, sub-cutaneously. The cells were allowed to form
solid tumor for two weeks before starting the measurement of the
tumor size. The tumor size was then measured in all animals
starting from the third week and every week after that. Treat-
ments were started at fourth week of the tumor cell inoculation.
For radiotherapy, 8 Gy single dose was treated to the ﬂank region
bearing tumor with Clinac 21EX Linear Accelerator once a week for
three weeks. For cisplatin chemotherapy, the mice were treated
with 2 mg/kg cisplatin in PBS intraperitoneally once a week at
about 4–6 h before radiotherapy. For GSNO treatment, the mice
were treated with 10 mg/kg GSNO in PBS for ﬁve days a week
intraperitoneally. The GSNO treatments continued for 6 weeks. In
one set of animals, GSNO treatment was withdrawn at 3 weeks of
treatment initiation.2.6. Bioluminescent imaging
Non-invasive measurement of tumor size was performed by
bioluminescent imaging of ﬁreﬂy luciferase expressing SCC14a
cells every week. Mice were anesthetized by inhalation of 1–2%
isoﬂuorane (Aerrane; Baxter Healthcare Corp, Deerﬁeld, IL) and
intraperitoneally injected with 200 mL D-luciferin (150 mg/kg;
Biosynth AG, Staad, Switzerland). Images were acquired every
2 min for 30 min (10 s exposure/image). Xenogen IVIS 200 biolu-
minescent/ﬂuorescent imaging system (PerkinElmer, Waltham,
MA) was used and the images obtained were analyzed by Living
Images software (PerkinElmer), and the photons emitted was
measured as p/s/cm2/sr and calculated as a ratio to the control.
2.7. Statistical analysis
Statistical analysis was performed with Graphpad Prism5. Va-
lues are expressed as mean7standard error mean. Comparisons
among means of groups were made with a two-tailed Student's t-
test for unpaired variables. Multiple comparisons were performed
using one-way ANOVA followed by Bonferroni test.3. Results
3.1. GSNO treatment decreases STAT3 activity (phosphorylation) in
HNSCC cells
Based on the fact that activated STAT3 (phosphorylated STAT3)
is involved in tumor growth, angiogenesis and invasion and that
GSNO, an endogenous nitrosylating agent, can inhibit activation of
STAT3 via S-nitrosylation of Cysteine 259 residue [15–17], we
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three human oral cancer cell lines; SCC1, SCC14a and SCC22a. All
three cell lines were treated with different concentrations of GSNO
twice (12 h interval) and changing the media and harvested at
24 h. Fig. 1A shows that all these HNSCC cell lines had con-
stitutively phosphorylated STAT3 (pSTAT3). GSNO treatment for
24 h decreased the basal pSTAT3 levels in a dose dependent
manner. Further, single treatment of SCC14a cells with GSNO re-
sulted in the reversal of the STAT3 phosphorylation over 24 h,
indicating that GSNO is continuously required for its inhibitory
activity on STAT3 activation and that this effect is reversible
(Fig. 1B). The representative images of the STAT3 and pSTAT3
immuno staining of cells with or without GSNO treatment also
reveal the inhibition of STAT3 phosphorylation by GSNO (Fig. 1C).
These observations suggest that GSNO mediated inhibition of
STAT3 activation may inhibit the pro-oncogenic pathways (such as
proliferation and survival) in cancer cells.
3.2. GSNO treatment decreases cell survival and proliferation and
inhibits cell cycle progression in HNSCC cells
Next, we investigated the effect of GSNO on proliferation/sur-
vival of HNSCC cells. Fig. 2A shows that GSNO treatment decreased
the cell number in a concentration dependent manner. We also
examined the effect of GSNO treatment on HNSCC cell prolifera-
tion by BrdU incorporation assay. As shown in Fig. 2B, GSNOFig. 2. Effect of GSNO treatment on HNSCC cell survival, proliferation, and cell cycle prog
different concentrations of GSNO, the cell survival (A) and proliferation (B) assay were pe
for 24 h and then the cell cycle analysis by propidium iodide staining (C-i) was perform
effect of GSNO on cell survival and cell cycle regulators (e.g. Bcl-xL, cIAP, and c-Myc) (C-iv
graphs were given as mean of at least three independent experiments. The vertical lines
groups.treatment decreased the proliferation of all three HNSCC cell lines
tested. The effect of GSNO treatment on cell cycle of SCC14a cells
was carried out by ﬂow cytometry of propidium iodide stained
cells (Fig. 2C-i). Fig. 2C-ii shows that GSNO treatment signiﬁcantly
increased the percentage of cells in the S and G2 phase while
decreasing the proportion of cells in G1 Phase as compared to
untreated controls, indicating that the GSNO mediated mechan-
isms induce cell cycle arrest in S and G2 phases. In addition to cell
cycle arrest, GSNO treatment also increased the number of apop-
totic cells (Fig. 2C-iii). Consistent with the observed increases in
apoptosis and cell cycle arrest, GSNO treatment decreased the
expression levels of cell survival and cycle regulators, such as Bcl-
xL, cIAP, and c-Myc, which are known to be regulated by STAT3
and NF-κB [33–36]. These studies indicate that GSNO is a potential
regulator of cell cycle and cell survival pathways in HNSCC cells.
3.3. GSNO treatment enhances radiation induced HNSCC cell death
Next, we studied whether GSNO mediated mechanisms will
complement effect of radiation therapy. To determine whether the
GSNO treatment would complement radiotherapy, HNSCC cells
were treated with 10 Gy radiation and then immediately treated
with GSNO (250 mM; 12 h interval with change of medium) for
24 h, and analyzed for status of STAT3 activity (Fig. 3A). In addi-
tion, time course of HNSCC cell survival was also evaluated fol-
lowing the treatment with GSNO and radiation (Fig. 3B). In allression. Following the treatment of SCC1, SCC14a and SCC22a HNSCC cell lines with
rformed as mentioned in the methods. SCC14a cells were treated with 250 μM GSNO
ed. The percentage of cells in each cell cycle phase (C-ii) and apoptosis (C-iii) and
) were analyzed by ﬂow cytometry and Western analysis. The results in bar and line
indicate the standard deviation; ***Po0.001 compared with vehicle treated control
Fig. 3. Effect of GSNO treatment and radiation on STAT3 activities and HNSCC cell
survival. (A) Following the treatment of SCC1, SCC14a and SCC22a HNSCC cell lines
with 10 Gy radiation and 250 μM GSNO for 24 h, the levels of STAT3 and their
phosphorylated forms were analyzed by Western analysis using speciﬁc antibodies.
The densitometry values as compared to that of control calculated by using NIH-
Image-J. (B) HNSCC cell lines were treated with 10 Gy radiation and 250 μM GSNO
for indicated time and the cell survival was analyzed as described under Section 2.
The results in bar and line graphs were given as mean of at least three independent
experiments. The vertical lines indicate the standard deviation; *Po0.05;
**Po0.01; compared with vehicle (VHC; dimethylsulfoxide) treated control groups.
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STAT3 activities (phosphorylation) (Fig. 3A). Fig. 3B for cell survival
assay shows greater efﬁcacy with combination of GSNO and ra-
diation than individual treatments. These results indicate that
GSNO treatment of HNSCC cells enhances radiation-induced
growth inhibition by downregulating STAT3 activity.
3.4. GSNO inhibits NF-κB activity and iNOS expression but increases
HIF1-α levels without inducing VEGF secretion
NF-κB is a crucial transcription factor for cancer cell survival
and chemoresistance [7]. To assess the role of GSNO in NF-κB
activation in HNSCC cells, SCC14a cells were treated with GSNO for
3 h and then treated with proinﬂammatory cytokines (25 ng/ml
TNF-α, 25ng/IL-1β, and 25 ng/ml IFN-γ) for 15 min. Fig. 4A shows
that GSNO treatment inhibited the NF-κB activation measured as
decreased nuclear translocalization of p65 (NF-κB) (Fig. 4A-i) as
well as its DNA binding activity (Fig. 4A-ii) under both control and
cytokine stimulated conditions.
The inducible form of NO synthase (iNOS) has been implicated
both in anti-cancer and pro-cancer cell signaling processes [37,38].
iNOS produces NO as well as superoxide anion radical (O2)
depending on the cellular redox status and substrate and cofactoravailabilities. High levels of NO and O2 are described to trigger
apoptosis of cancer cells [39–41]; however their sustained low
levels are reported to contribute to cancer cell survival by pro-
moting cell death resistance signals [41,42], thus low and sus-
tained expression of iNOS could participate in promotion of cancer
cell survival. Fig. 4B shows that SCC14a cells under normal con-
ditions express low and sustained levels of iNOS. GSNO treatment
decreased the basal expression of iNOS in a dose dependent
manner. In addition, the basal levels of protein nitrotyrosine, ob-
served in cancer cells, was also decreased by treatment with GSNO
to the levels observed in the cells treated with NOS inhibitor (L-
Nω-nitroarginine methyl ester), thereby suggesting that GSNO
may be effective on the inhibition of basal expression of iNOS as
well as ONOO generation from NO and O2 in HNSCC cells.
Interestingly, the treatment of SCC14a cells with proinﬂammatory
cytokines did not result in increased expression of iNOS in spite of
NF-κB activation (Fig. 4A), indicating a mechanism for limiting the
overexpression of iNOS gene under proinﬂammatory conditions in
HNSCC cell line. The basis of these derangements in signaling for
inﬂammatory regulation of iNOS gene is not understood at pre-
sent, but these observations document that GSNO mediated me-
chanisms inhibit the induction of iNOS as well as NO associated
toxicity as nitrotyrosine formation.
Hypoxic inducible factor-1α (HIF-1α) activation and tumor-
angiogenesis by vascular endothelial growth factor (VEGF) release
were described as potential mechanisms for NO-mediated tu-
morigenesis and metastasis [22,43,44]. As NO is known to stabilize
HIF-1α by S-nitrosylation dependent mechanisms [44], we ob-
served that GSNO treatment also increased HIF-1α levels in both
nucleus and cytoplasm (Fig. 4C). Although HIF-1α is one of pre-
requisites for induction of VEGF gene expression [22,43], we did
not observe increase in VEGF secretion by GSNO treatment
(250 μM for 17 h) of SCC14a cells (Fig. 4D). Instead, GSNO treat-
ment slightly, but signiﬁcantly, decreased VEGF secretion by
SCC14a cells under normal conditions. Proinﬂammatory cytokines
are known to induce VEGF gene expression in various cell types
[45,46]. GSNO pretreatment of SCC14a cells, 3 h prior to cytokine
treatment (TNF-α, IL-1β, and IFN-γ; 25 ng/ml each/14 h incuba-
tion), also inhibited cytokine-induced VEGF secretion (Fig. 4D).
These data indicate that regardless of activation of HIF-1α, exo-
genous GSNO does not induce VEGF-dependent angiogenesis.
3.5. GSNO enhances efﬁcacy of radiation and cisplatin therapy in
HNSCC cancer xenograft mouse model
An animal xenograft model was generated by injection of nude
mice with luciferase labeled SCC14a into the ﬂank. Tumors were
allowed to establish for 4 weeks prior to initiation of treatments.
The mice were then treated with radiotherapy (8 Gy; one a week
for three times) or cisplatin (2 mg/kg body weight; one a week for
three times) or GSNO (10 mg/kg body weight; one a day till 10th
week following the transplantation) individually or in combina-
tion as described in methods section (n¼11 per group). The tumor
size was measured by bioluminescent imaging (Fig. 5A and B).
GSNO treatment signiﬁcantly decreased the tumor size in the
HNSCC xenografted animals as compared to radiation or cisplatin
treatments alone. GSNO treatment in combination with radio-
therapy and/or cisplatin further decreased the growth of tumor.
Because GSNO inhibited STAT3 phosphorylation reversibly, we
examined whether GSNO treatment inhibits tumor growth re-
versibly. Fig. 5B shows that discontinuation of GSNO treatment at
7th week in the mice treated with cisplatin and radiation re-
versibly increased the tumor growth, indicating that GSNO treat-
ment increased the therapeutic potential of cisplatin and radio-
therapy in a reversible manner.
Fig. 4. Effects of GSNO treatment on NF-κB activities and expressions of iNOS, HIF-1α, and VEGF. (A) Following the treatment with GSNO (250 μM) for 3 h, the SCC14a cells
were treated with cytokine mix (TNFα, IL-1β, and IFN-γ; 25 ng/ml each) for 20 min. The nuclear and cytoplasmic levels of p65 NF-κB (i) and nuclear NF-κB DNA binding
activities (ii) were analyzed by Western and gel-shift assay. H3 histone (H3) and β-actin were used as an internal loading control. (B) Following the treatment of SCC14a cells
with GSNO, cytokines, and/or L-NAME (250 μM) for 12hrs, the expression of iNOS (i) and cellular nitro-tyrosine (N-Tyr) (ii) levels were investigated byWestern analysis using
speciﬁc antibodies. (C) Time course effect of GSNO (250 μM) on cellular HIF-1α levels was analyzed byWestern blot. (D) GSNO induced inhibition of VEGF secretion in SCC14a
cell cultures were analyzed. SCC14a cells were pretreated with GSNO (250 μM for 3 h) and then treated with/without cytokine mix (TNFα, IL-1β, and IFNγ; 25 ng/ml each/14 h
incubation). Following the incubation, human VEGF levels were analyzed by ELISA assay. The results in bar and line graphs were given as mean of at least three independent
experiments. The vertical lines indicate the standard deviation; *Po0.05; **Po0.01; ***Po0.001; compared with vehicle treated control groups. (D) Two way ANOVA was
used for statistical analysis for differences between control vs. cytokine treated groups (###Po0.001).
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STAT3 activation and enhances tumor cell death in HNSCC xeno-
grafted mice
STAT3 activation increases cell cycle progression, proliferation,
and survival of tumor cells by upregulating the expression and
activities of its down-stream genes, such as VEGF, and Bcl-2 [5,47].
To examine the effect of GSNO on STAT3 activation and STAT3
regulated gene expression, tumor tissues harvested from xeno-
grafted mice treated with vehicle, cisplatin, radiation, and/or
GSNO (10th week following the transplantation) were used for
Western analysis for phospho/total-STAT3, VEGF, and Bcl-2. All
experiments were performed at least three times (total n¼6 mice
per group). Consistent with our cell culture studies (Figs. 1 and 2),
GSNO treatment decreased pSTAT3 levels in tumor tissues har-
vested from HNSCC xenograft mouse model (Fig. 6A). Accordingly,
GSNO treatment also reduced the expression of tumor growth
regulators, such as VEGF and Bcl-2, thereby suggesting a potential
inhibitory effect of GSNO on STAT3-mediated tumor progression in
HNSCC. Next we investigated the effect of GSNO treatment on
tumor cell survival in combination with radiation and/or cisplatin
treated xenograft mice. Fig. 6B shows that GSNO treatment alone
and in combination with other treatments signiﬁcantly increased
the apoptosis reﬂected as increased TUNEL positive cells. The
above observations indicate that GSNO controls the growth ofcancer and also complements radiotherapy and chemotherapy for
a greater degree of efﬁcacy.4. Discussion
Studies from our laboratory and others have documented that
activities of STAT3 and NF-κB are regulated by redox based post-
translational modiﬁcation mediated by NO (S-nitrosylation)
[10,11,15,16,48,49]. STAT3 plays key roles in the regulation of gene
expression for cell survival (i.e. Bcl-xL, cIAP, survivin, and Mcl-1),
cell cycle (i.e. c-myc, CDK2, Cyclin-E, CDK1, and Cyclin-B), and
tumor angiogenesis (i.e. vascular endothelial growth factor; VEGF)
[33,34,50–57]. Similarly, NF-κB also participates in regulation of
gene expression for cell survival (i.e. cIAP, Bcl-2, Bcl-xL, and XIAP),
cell cycle (i.e. c-Myc and Cyclin D), and multidrug resistance (e.g.
MDR1) [35,36,58–60]. Studies described here document that
treatment with GSNO, an endogenous S-nitrosothiol compound,
may hold potential to target aberrant STAT3 and NF-κB activation
in HNSCC and may complement conventional cancer treatments,
such as radiation and cisplatin, to achieve greater efﬁcacy against
tumor growth. These conclusions are based on the following ob-
servations: (1) GSNO treatment of HNSCC cells in vitro reversibly
inhibited the activation of STAT3. (2) The inhibition of STAT3 ac-
tivation by GSNO treatment correlated with the inhibition of
Fig. 5. Effects of radiation, cisplatin and GSNO and their combinations on tumor growth in HNSCC xenografted mice. (A) Nude mice were injected with luciferase labeled
SCC14a cells (106) and the tumor growth was evaluated by ﬂuorescence intensity after 6 weeks of treatments with the respective protocol. (B) The animals were treated with
radiation, cisplatin, and/or GSNO 4 weeks after inoculation of cancer cells, and the time-course changes in tumor size (ﬂuorescence intensity) were measured. To investigate
the reversibility in GSNO-inhibited tumor growth, GSNO treatment was discontinued for a group mice treated with cisplatin and radiation after 7 weeks (solid red diamond).
The data are mean7standard error from six animals in each group.
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(3) GSNO treatment with radiation in in vitro cultures inhibited
the STAT3 activation to a higher degree than GSNO or radiation
treatment alone. (4) GSNO treatment alone or in combination with
cisplatin and radiation reversibly reduced the tumor mass in
HNSCC xenograft mouse model. These observations clearly docu-
ment that GSNO treatment reversibly inhibit the activation of
STAT3 and NF-κB and tumor growth in in vitro cell culture model
and in vivo xenograft model of HNSCC. Since STAT3 modulates
various physiological functions, its persistent and irreversible in-
hibition may cause side effects on other physiological functions. In
this aspect, the reversible inhibition of STAT3 by GSNO is parti-
cularly beneﬁcial for clinical cancer treatment.
STAT3 activation in HNSCC cells was found to be mediated by
the gp130 cytokine receptor [61,62]. Activation of gp130 is pri-
marily driven by the inﬂammatory cytokine IL-6 which is pro-
duced by HNSCC cells themselves [63]. Interestingly, production of
IL-6 by HNSCC cells requires NF-κB activity as the inhibition of NF-
κB led to down-regulation of IL-6 expression [61,64], thus doc-
umenting the importance of inhibition of cross-talk between the
NF-κB and the STAT3 signaling system in HNSCC therapeutics. In
this study, we observed that GSNO treatment inhibited not only
STAT3 (Fig. 1) but also NF-κB (Fig. 4), thus indicating the efﬁcacy of
GSNO-mediated S-nitrosylation mechanism on inhibition of cross-
talk between STAT3 and NF-κB pathways in HNSCC.
NOS expression has been observed in many human cancers
where NO produced by NOS have been reported to be both pro-
and anti-tumor [21–27]. In xenograft mouse model of hepatoma,
implantation of eNOS-overexpressing hepatoma cells as well as
injection of NO donor into wild-type hepatoma-derived tumors
resulted in increased hepatoma cell death and reduced tumor cellgrowth [65]. In addition, NO compounds, such as diethylamine
dinitric oxide [25] and nitroglycerin [28], NO-nonsteroidal anti-
inﬂammatory drugs [29] have been reported to enhance chemo-
sensitization of tumor. GSNO treatment was reported to inhibit
cell growth and promote apoptosis in colon cancer cell lines [66]
and nitrosylcobalamin promoted cell death via nitrosylation of
Apo2L/TRAIL receptor DR4 in several human cancer cell lines [26].
In this study, we demonstrated that treatment of HNSCC cells with
GSNO, an endogenous NO carrier molecule, inhibited proliferation
and survival of HNSCC cells via inhibiting activities of STAT3 and
NF-κB, suggesting the role of NOS and thus NO/GSNO in inhibition
of cancer growth and survival.
NOS produces not only NO but also O2 depending on cellular
redox conditions and cofactor (tetrahydrobiopterine/BH4) avail-
ability [67]. NOS coupled with BH4 generates NO and L-citrulline
from L-arginine. However, under oxidative stress conditions and
limiting availability of cofactor and/or L-arginine, uncoupled NOS
generates O2 more than NO and also leads to production of
peroxynitrite (ONOO). Formation of high amounts of O2 and
ONOO is known to trigger cancer cells into apoptosis [39–41]. On
the other hand, their sustained low levels could contribute to
cancer cell survival by promoting cell death resistance signals via
activation of NF-κB [41,42,68,69]. In turn, this low and sustained
expression of iNOS could participate in promotion of cancer cell
survival via O2/ONOO induced NF-κB activation. GSNO is
known to inhibit activation of NF-κB, a prerequisite for iNOS ex-
pression, via S-nitrosylation dependent mechanisms
[10,11,48,70,71]. Accordingly, we observed that GSNO treatment
attenuated sustained low-level activation of NF-κB (Fig. 4A) and
iNOS expression (Fig. 4B-i). In addition, GSNO treatment atte-
nuated sustained low levels of protein nitrotyrosine content in
Fig. 6. Effects of radiation, cisplatin and GSNO and their combinations on STAT3
activity and its downstream protein expression in HNSCC xenografted mice.
(A) Western analysis of the tumor tissues harvested from control and experimental
animals for STAT3, pSTAT3, VEGF, Bcl-2, or β-actin was performed. (B) The tumor
tissues were subjected to TUNEL assay for detection of the cells undergoing
apoptosis. The sections were counterstained with DAPI for detection of nuclei.
(i) The number of TUNEL positive cells was counted in 10 different regions of the
slides (two regions from each animal) (ii). The results in bar graphs were given as
mean of at least three independent experiments. The vertical lines indicate the
standard deviation; *Po0.05; **Po0.01; ***Po0.001; compared with vehicle
treated control groups.
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trotyrosine content in SCC14a cells by iNOS inhibitor (L-NAME)
suggests the possible role of GSNO mediated mechanisms in at-
tenuation of iNOS-dependent sustained low-level of nitrosative
stress.
NO has been reported to stabilize HIF-1α, key transcription
factors for VEGF expression [22,43] under normoxic conditions by
S-nitrosylation dependent mechanisms [44]. Therefore, HIF-1α
activation and induction of tumor-angiogenesis via VEGF releasewere described as potential mechanisms for NO-mediated tu-
morigenesis and metastasis [22,43,44]. Indeed, GSNO was re-
ported to induce VEGF expression in cultured keratinocytes during
the cutaneous wound repair [72]. Consistent with the previous
studies, we also observed that GSNO treatment induced cellular
and nuclear accumulation of HIF-1α (Fig. 4C). However, GSNO
treatment decreased the VEGF expression both in in vitro cell
culture study (Fig. 4D) and in tumor tissues from HNSCC xeno-
grafted mice (Fig. 6A). VEGF expression is regulated by several
transcription factors including AP-1, STAT-3, LXR, Sp1, AP-2 and
Egr-1 in addition to HIF-1α [47]. Among them AP-1, Sp1, Egr-1, and
STAT3 have been reported to be inhibited by S-nitrosylation de-
pendent mechanisms [16,73] (Figs. 1, 3, and 6), suggesting that
GSNO-mediated regulation of VEGF expression is more complex
than the simple activation of HIF-1α by S-nitrosylation. Con-
stitutive STAT3 activity is reported to up-regulate VEGF expression
and tumor angiogenesis [74]. Since GSNO inhibits STAT3 activity
(phosphorylation of Tyr705) via S-nitrosylation of its Cys259 residue
(Fig. 1) [16], we speculate that GSNO inhibits VEGF expression via
inhibiting STAT3 activity. The detailed molecular mechanisms
underlying the role of GSNO in regulation of VEGF expression
would be further elucidated in future studies.
A combination of systemic cisplatin and loco-regional radio-
therapy are widely used in head and neck cancer. However, pa-
tients treated with chemoradiation can eventually relapse from
minimal residual cancer in a similar way to patients who are
primarily treated with surgery. In addition, the majority of re-
lapsed cancers develop cisplatin-resistance. Cisplatin resistance is
complex and involves several mechanisms. Increased activities of
Akt/mTOR pathways were reported to participate in cisplatin re-
sistance in ovarian cancer [75]. In addition, the increased expres-
sions and activities of STAT3 and NF-κB have been also associated
with cisplatin resistance via upregulating the cancer cell survival
factors (i.e. Bcl-2 and Bcl-xL) and multidrug resistance molecules
[76,77]. In summary, this study reports that GSNO efﬁciently reg-
ulates STAT3 and NF-κB activities in HNSCC cell lines (SCC1,
SCC14a and SCC22a) in cell culture as well as in tumor tissues from
radiation, cisplatin, and GSNO treated xenograft mice. The efﬁcacy
of GSNO treatment in attenuation of tumor growth by itself or in
combination with cisplatin and/or radiation suggests a potential
utility of GSNO-mediated mechanisms not only as stand alone
cancer therapy but also in management of cancer relapse as a
maintenance drug following chemoradiation therapy and cisplatin
resistance.Acknowledgments
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